Substitute for form 1449A/PTO		Co			
Subsubile for form 1445AVF 10	,		Application Number	Not Yet Assigned	
INFORMATION	N DISC	LOSURE	Filing Date	Even Date Herewith	
STATEMENT I	ΑΥ ΔΡ	PLICANT	First Named Inventor	Mitsuhiro UENO et al	
OIA CINEII	<i>5</i> .	. 2.07	Group Art Unit	1636	
(use as many	sheets as n	ecessary)	Examiner Name	GUZ0	
Sheet 1	of	2	Attorney Docket Number	UENO =8A	

<u> </u>	U.S. PATENT DOCUMENTS						
		U.S. Patent		Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or	
Examiner I	Cite No.	Number	Kind Code ² (if known)	of Cited Document	MM-DD-YYYY	Relevant Figures Appear	
DG	AA	5,856,456		STOUT et al	08-12-1997		
DG	AB	6,013,628		SKUBITZ et al	01-2000		
DG	AC	6,146,885		DORNBURG	11-2000		
DG	AD	6,426,042		ASADA et al	07-2002		
DG	AE	6,472,204		ASADA et al	10-2002		
DG	AF	8,472,212		VALERIO et al	10-2002		
					1		
					1		
1							

				FORE	IGN PATENT DOCUME	NTS		
Examiner Initials*	Cite No.	Office ³		(ind Code ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т°
DG	AG	JP	8-317785		KANAGAWA KAGAKU GIJUTSU AAKAD	03-12-1996		
DG	АН	wo	97/11604		INDIANA UNIVERSITY FOUNDATION	04-03-1997		
DG	Al	wo	92/00524		MEDICAL RESEARCH COUNCIL; THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD	01-09-1992		
DG	AJ	wo	97-18318		TAKAHARA SHUZO CO., LTD.	05-22-1997		
DG	AK	EP	0 521 733		SAKAI ENEX KABUSHIKI KAISHA	03-17-1993		
DG	AL	EP	0 870 839	1,	ASADA et al.	Oct. 14, 1998		
DG	AM	EP	0 844 004		TERADA et al.	May 27, 1998		
DG	AN	PCT	95 26200		WILLIAMS et al.	Oct. 5, 1995		
				_ L				

Examiner Signature	/David Guzo/	Date Considered	09/23/2006

^{*} EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	Not Yet Assigned	
INF	ORMATIC	ON DISC	CLOSURE	Filing Date	Even Date Herewith	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Mitsushiro UENO et al	
•				Group Art Unit	1636	
	(use as ma	ny sheets as r	necessary)	Examiner Name	GUZO	
She	eet 2	of	2	Attorney Docket Number	UENO =8A	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
AO	CHU et al., "Retroviral Vector Particles Displaying the Antigen-Binding Site of an Antibody Enable Cell-Type- Specific Gene Transfer", JOURNAL OF VIROLOGY, vol. 69, No. 4, pp. 2659-2663, (1995)	
AP	Cytomegalovirus Gene Expression in Human Primary Monocyte/Macrophages in Vitro*; JOURNAL OF LEUKOCYTE BIOLOGY, Federation of American Societies for Experimental; Vol. 53, no. 2, February 1993; pp.	
AQ		
	MORITZ et al., "Fibronectin Improves Transduction of Reconstituting Hematopoietic Stem Cells by Retroviral Vectors: Evidence of Direct Viral Blnding to Chymotryptic Carboxy-Terminal Fragments", BLOOD, vol. 88, No. 3, pp. 855-862, (1996)	
	OLSEN et al, "Use of Sodium Butyrate to Enhance Production of Retroviral Vectors Expressing CFTR cDNA", HUMAN GENE THERAPY, Vol. 6, 1995, pp. 1195-1202.	
AT	PAGES et al; Activation of Moloney Murine Leukemla Virus LTR Enhances the Titer of Recombinant Retrovirus in psi-CRIP Packaging Cells"; GENE THERAPY; Vol. 2, No. 8, October 1995; pp. 547,551.	
AU	SAPPEY et al; Iron Chelation Decreases NF-kB and HIV type I Activation Due to Oxidative Stress*; AIDS RESEARCH AND HUMAN RETROVIRUSES; Vol. 11, No. 9, 1995, pp. 1049-1061.	
	·	
	AP AQ AR AS	Cite No. Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published AO CHU et al., "Retroviral Vector Particles Displaying the Antigen-Binding Site of an Antibody Enable Cell-Type-Specific Gene Transfer", JOURNAL OF VIROLOGY, vol. 69, No. 4, pp. 2659-2663, (1995) AP HO et al; "Centrifugal Enhancement of Human Immunodeficiency Virus Type I Infection and Human Cytomegalovirus Gene Expression in Human Primary Monocyte/Macrophages in Vitro"; JOURNAL OF LEUKOCYTE BIOLOGY, Federation of American Societies for Experimental; Vol. 53, no. 2, February 1993; pp. 208-212 AQ MORITZ et al., "Bone Marrow Extracellular Matrix Molecules Improves Gene Transfer Into Human Hematopoletic Cells via Retroviral Vectors", J. CLIN. INVEST, vol. 93, pp. 1451-1457, (1994) AR MORITZ et al., "Fibronectin Improves Transduction of Reconstituting Hematopoletic Stem Cells by Retroviral Vectors: Evidence of Direct Viral Binding to Chymotryptic Carboxy-Terminal Fragments", BLOOD, vol. 88, No. 3, pp. 855-862, (1996) AS OLSEN et al, "Use of Sodium Butyrate to Enhance Production of Retroviral Vectors Expressing CFTR cDNA", HUMAN GENE THERAPY, Vol. 6, 1995, pp. 1195-1202. AT PAGES et al; Activation of Moloney Murine Leukemia Virus LTR Enhances the Titer of Recombinant Retrovirus in psi-CRIP Packaging Cells"; GENE THERAPY; Vol. 2, No. 8, October 1995; pp. 547,551. AU SAPPEY et al; Iron Chelation Decreases NF-kB and HIV type I Activation Due to Oxidative Stress"; AIDS

Signature	Examiner Signature	/David Guzo/	Date Considered	09/23/2006
-----------	-----------------------	--------------	--------------------	------------

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English tanguage Translation is attached.

NOV 2 ? 7005 W

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	10/657,076			
Filing Date	September 9, 2003			
First Named Inventor	Mitsuhiro UENO			
Group Art Unit	1636			
Examiner Name	David Guzo			
Attorney Docket Number	UENO=8A			

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (III} Innorm)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-		- " 	
		US-			
		US-			
		US-	,		
		US-			

		FORE	IGN PATENT DO	DCUMENTS	•	
		Foreign Patent Number	Dublication Date	Name of Detector or Applicant	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country-Code ³ Number ⁴ Kind Code ⁵ (# knawn)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
DG	AV	JP-A 9-509303	09-22-1997			
DG	AW	WO 95/10619	04-20-1995 .	PALSSON et al.		
						Ш
			1		·	

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
DG		SALONEN, et al. Retrovirus RD114 p30 is bound by the extracellular matrix proteins, fibronectin and laminin, Virus Research, Vol. 1 (1984), pp. 427-431.	

Examiner Signature	/David Guzo/	Date Considered	09/23/2006

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kind Codes of USPTO Patent Documents at www.uspto.gog or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.